A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi‐institutional retrospective study in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi‐institutional retrospective study in Japan

Published:2022-12-28 Issue: Volume: Page:
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Kato Taigo¹^ORCID,Yumiba Satoru¹,Nakata Wataru²^ORCID,Nakano Kosuke³,Nagahara Akira⁴,Matsuzaki Kyosuke⁵^ORCID,Hayashi Yujiro⁶,Hatano Koji¹,Kawashima Atsunari¹^ORCID,Takao Tetsuya⁶^ORCID,Nishimura Kensaku⁵,Nakai Yasutomo⁴,Nakayama Masashi⁴,Nishimura Kazuo⁴,Takada Shingo³,Tsujihata Masao²,Uemura Motohide¹,Nonomura Norio¹,Imamura Ryoichi¹

Affiliation:

1. Department of Urology Osaka University Graduate School of Medicine Suita Osaka Japan

2. Departments of Urology Osaka Rosai Hospital Sakai Osaka Japan

3. Department of Urology Osaka Police Hospital Tenoji‐ku Osaka Japan

4. Department of Urology Osaka International Cancer Institute Chuo‐ku Osaka Japan

5. Department of Urology National Hospital Organization Osaka National Hospital Chuo‐ku Osaka Japan

6. Department of Urology Osaka General Medical Center Sumiyoshi‐ku Osaka Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15130

Reference21 articles.

1. Epidemiology and risk factors for kidney cancer

2. Cancer statistics, 2019

3. Epidemiology of Renal Cell Carcinoma

4. Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012

5. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience;Medicine;2023-10-13

2. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study;International Journal of Urology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3